Renaissance Technologies LLC Grows Stock Holdings in Teladoc Health, Inc. $TDOC

Renaissance Technologies LLC increased its position in Teladoc Health, Inc. (NYSE:TDOC) by 1.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 8,085,542 shares of the health services provider’s stock after buying an additional 107,400 shares during the period. Renaissance Technologies LLC owned about 4.48% of Teladoc Health worth $44,066,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after purchasing an additional 5,235 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after buying an additional 10,485 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Teladoc Health by 5.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after acquiring an additional 24,124 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Teladoc Health in the 1st quarter valued at $615,000. Finally, Envestnet Asset Management Inc. purchased a new stake in Teladoc Health in the 2nd quarter worth $89,000. 76.82% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Fernando M. Rodrigues sold 5,677 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider directly owned 9,572 shares of the company’s stock, valued at $73,034.36. This trade represents a 37.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer directly owned 389,894 shares in the company, valued at approximately $2,974,891.22. This represents a 4.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock valued at $299,058 over the last quarter. Company insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

TDOC has been the subject of a number of research analyst reports. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Citigroup boosted their target price on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Canaccord Genuity Group increased their price target on Teladoc Health from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Bank of America raised their price target on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.57.

Teladoc Health Stock Performance

Teladoc Health stock opened at $8.89 on Tuesday. The company’s 50-day moving average price is $8.10 and its 200-day moving average price is $6.52. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The company has a market cap of $1.61 billion, a PE ratio of -9.17 and a beta of 2.10. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The business had revenue of $613.85 million during the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm’s revenue was down 2.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, equities research analysts forecast that Teladoc Health, Inc. will post -0.92 EPS for the current fiscal year.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.